Dark

IMTX
Immatics N.V.
stock NASDAQ

At Close

Aug 29, 2025 3:59:55 PM EDT

5.09USD-3.598%(-0.19)2,563,570

0.00Bid 0.00Ask 0.00Spread

Pre-market

Aug 28, 2025 8:01:30 AM EDT

5.30USD+0.379%(+0.02)0

After-hours

Aug 29, 2025 4:00:30 PM EDT

5.09USD0.000%(0.00)9,305

OverviewOptionsHistoricalExchangesShortsNews

Jan 25, 2022

06:13AM EST Immatics Biotechnologies Granted U.S. Patent #11,230,581 'Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers' Benzinga

Jan 4, 2022

06:18AM EST Immatics Biotechnologies Granted U.S. Patent #11,214,604 'Peptides for use in immunotherapy against cancers' Benzinga

Dec 28, 2021

06:08AM EST Immatics Biotechnologies Granted U.S Patent #11,208,434 'Immunotherapy against several tumors including neuronal and brain tumors' Benzinga

Dec 14, 2021

09:45AM EST Immatics Shares Quiet Following Trader Circulation Of SVB Leerink Note Showing Raised Price Target To $32 Benzinga

07:58AM EST Immatics Biotechnologies Granted U.S. Patent #11,197,89 'Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers' Benzinga

07:01AM EST Immatics And Bristol Myers Squibb Enter Into Global Exclusive License For Immatics' TCR Bispecific Program; Immatics To Receive $150M Upfront Payment And Additional Milestones Of Up To $770M Benzinga

06:59AM EST -- Bristol Myers Squibb secures global exclusive license to Immatics TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-promotion option in the US -- Immatics to receive upfront payment of $150 million and additional milestone payments of up to $770 million plus tiered double-digit royalties on net product sales GlobeNewswire Inc

Nov 16, 2021

07:43AM EST Immatics Q3 Sales $7.40M Down From $9.10M YoY Benzinga

07:00AM EST Immatics Announces Third Quarter 2021 Financial Results and GlobeNewswire Inc

Nov 9, 2021

11:44AM EST Immatics Reports Clinical Responses Across Multiple Solid Tumor Types In Ongoing ACTengine IMA203 Phase 1a Trial Targeting PRAME Benzinga

08:00AM EST Immatics Reports Clinical Responses across Multiple Solid Tumor GlobeNewswire Inc

Nov 1, 2021

08:12AM EDT Immatics To Present Update On Lead ACTengine Program IMA203 Targeting PRAME At The Society For Immunotherapy Of Cancer's 36th Annual Meeting Benzinga

08:00AM EDT Immatics to Present Update on Lead ACTengine Program GlobeNewswire Inc

Oct 29, 2021

02:08PM EDT Immatics Option Alert: Nov 19 $15 Calls at the Ask: 1000 @ $2.2 vs 3539 OI; Earnings 12/1 Before Open [est] Ref=$14.13 Benzinga

Aug 10, 2021

09:17AM EDT Immatics Q2 Net Loss EUR 23.8 Mln Vs Loss EUR 21.3 Mln Last Year RTTNews

07:44AM EDT Immatics: Q2 Earnings Insights Benzinga

07:25AM EDT Immatics Q2 Sales $6.20M Down From $8.20M YoY Benzinga

07:00AM EDT Immatics Announces Second Quarter 2021 Financial Results and GlobeNewswire Inc

Aug 2, 2021

09:26AM EDT Immatics Files For Mixed Shelf Of Up To $500 Benzinga

Jul 15, 2021

04:45AM EDT SVB Leerink Maintains Outperform on Immatics, Raises Price Target to $27 Benzinga

Jul 7, 2021

11:27AM EDT BioCopy, Immatics Team Up For Characterization Of TCR-Peptide-HLA Interactions Benzinga

03:00AM EDT BioCopy AG and Immatics enter into a collaboration to characterize T cell PR Newswire

Jun 29, 2021

08:33AM EDT Selexis And KBI Biopharma Enter Into Agreements With Immatics For Integrated Approach To Advance Immatics TCR Bispecific Program Towards IND Benzinga

Jun 15, 2021

10:31AM EDT Immatics Granted U.S. Patent Titled 'Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers' Benzinga

May 26, 2021

07:14AM EDT Christof Hettich To Step Down From Immatics' Board Of Directors RTTNews

07:00AM EDT Immatics Announces Changes to its Board of Directors GlobeNewswire Inc

May 18, 2021

07:10AM EDT Immatics Q1 Sales $8.70M Up From $8.20M YoY Benzinga

07:00AM EDT Immatics Announces First Quarter 2021 Financial Results and GlobeNewswire Inc

May 11, 2021

07:00AM EDT Immatics Presents Preclinical Proof-of-Concept Data for TCR GlobeNewswire Inc

Mar 30, 2021

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

07:00AM EDT -- Phase 1a data update from clinical ACTengine programs demonstrated first anti-tumor activity at early phases of dose escalation in heavily pre-treated solid cancer patients GlobeNewswire Inc

Mar 18, 2021

08:16AM EDT The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq Benzinga

01:25AM EDT Today's Daily Dose brings you news about Cannabics' drug candidate RCC-33 prolonging survival rate in mice inoculated with human colorectal cancer cells, encouraging data of Immatics' ACTengine program, and disappointing results from Translate Bio's cystic fibrosis trial. RTTNews

Mar 17, 2021

12:26PM EDT Mid-Day Market Update: Dow Gains 100 Points; Rubius Therapeutics Shares Plummet Benzinga

11:53AM EDT SVB Leerink Maintains Outperform on Immatics, Raises Price Target to $26 Benzinga

11:47AM EDT Immatics Price Target Raised From $17 To $26 At SVB Leerink Benzinga

11:40AM EDT Immatics Stock Trading Higher As Cell Therapy Program Shows Anti-Tumor Activities In Pretreated Cancer Patients Benzinga

10:39AM EDT Mid-Morning Market Update: Markets Mostly Lower; Cintas Profit Tops Views Benzinga

07:21AM EDT Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine Cell Therapy Programs Benzinga

07:00AM EDT Immatics Presents Data Update on Dose Escalation from Ongoing GlobeNewswire Inc

Mar 2, 2021

10:37AM EST Immatics Granted U.S. Patent Titled 'Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers' Benzinga

Feb 23, 2021

02:06PM EST Immatics Shares Quiet; Co Granted U.S. Patent Titled 'Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)' Benzinga

Jan 12, 2021

06:13AM EST Immatics Biotechnologies Awarded U.S. Patent 10,888,587 "Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers" Benzinga

Dec 2, 2020

07:15AM EST Immatics Q3 Net Loss EUR 177.1 Mln Or $207.3 Mln RTTNews

07:13AM EST Immatics Q3 Sales $7.87M Up From $5.06M YoY Benzinga

07:13AM EST Immatics Q3 Sales 7.87M Up From Benzinga

07:00AM EST -- ACTengine IMA200 clinical trial series continues scaling globally; initial analysis for patients in ACTengine dose escalation is on track for Q1 2021 GlobeNewswire Inc

Nov 10, 2020

07:00AM EST Immatics Presents Phase I Data from ACTolog GlobeNewswire Inc

Oct 29, 2020

07:36AM EDT Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4/8 Benzinga

07:00AM EDT -- Immatics first TCR Bispecific program IMA401 delivers preclinical proof-of-concept demonstrating complete remissions of transplanted human tumors in mice and favorable CMC characteristics GlobeNewswire Inc

Oct 9, 2020

09:10AM EDT Immatics NV Shares Quiet; Traders Circulate Dimensions Abstract Titled 'Immunotherapy against several tumors including gastrointestinal and gastric cancer' Mentioning Co's Drug Benzinga

Oct 1, 2020

03:42PM EDT Defiance NextGen SPAC IPO ETF Launches: What Investors Need To Know Benzinga

Sep 29, 2020

07:05AM EDT Immatics Appoints Arnd Christ as Chief Financial Officer Benzinga

Sep 22, 2020

09:36AM EDT Benzinga's Top Upgrades, Downgrades For September 22, 2020 Benzinga

06:42AM EDT Goldman Sachs Initiates Coverage On Immatics with Buy Rating, Announces Price Target of $17 Benzinga

Sep 15, 2020

07:00AM EDT Immatics Appoints Biotech Executive Eliot Forster to Board of GlobeNewswire Inc

Sep 10, 2020

07:08AM EDT Immatics Provides An Update On Its Fourth IMA204 ACTengine Cell Therapy Program Which Is Designed To Target The Tumor Microenvironment Benzinga

Sep 3, 2020

07:19AM EDT Immatics Q2 Total Revenue $7.7M, Net Loss $23.9M Benzinga

07:00AM EDT Immatics Announces Second Quarter 2020 Financial Results and GlobeNewswire Inc

Aug 18, 2020

07:00AM EDT Immatics Announces European Clinical Expansion of its Adoptive GlobeNewswire Inc

Aug 6, 2020

07:00AM EDT Immatics Extends Cell Therapy GlobeNewswire Inc

Jul 27, 2020

06:49AM EDT SVB Leerink Initiates Coverage On Immatics with Outperform Rating, Announces Price Target of $17 Benzinga

Jul 24, 2020

11:57AM EDT Jefferies Initiates Coverage On Immatics with Buy Rating, Announces Price Target of $14 Benzinga

.dark-mode .Nr0ryY{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .Nr0ryY{ color: #333333; background-color: white; border: 2px solid #333333; }IMTXImmatics N.V.stock NASDAQ

IMTX
Immatics N.V.
stock NASDAQ